MedTrace Logo

Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

NCT00137761 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2009-11-02

No results posted yet for this study

Summary

The purpose of this study is to find out what activity the combination of docetaxel and Iressa have against metastatic pancreatic cancer.

Conditions

  • Metastatic Pancreatic Carcinoma

Interventions

DRUG

ZD 1839

Taken orally once daily

DRUG

Docetaxel

Given intravenously once weekly for 2 out of 3 weeks

Sponsors & Collaborators

Principal Investigators

  • Matthew Kulke, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2007-06-30
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00137761 on ClinicalTrials.gov